vivus inc (VVUS) Key Developments

VIVUS Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. Total net revenue was $32.2 million in the current quarter, compared to $36.7 million in the first quarter of 2014. Net loss was $15.5 million, or $0.15 net loss per share, in the current quarter, compared to a net loss of $15.6 million, or $0.15 net loss per share, in the first quarter of 2014. Loss from operations was $6,824,000 against $7,928,000 a year ago.

VIVUS Inc. to Report Q1, 2015 Results on May 05, 2015

Apr 30 15

VIVUS Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 05, 2015

VIVUS Inc., Q1 2015 Earnings Call, May 05, 2015

Apr 30 15

VIVUS Inc., Q1 2015 Earnings Call, May 05, 2015

VIVUS, Inc. Announces Operational Update

Mar 30 15

VIVUS Inc. announced an operational update, including certain key corporate decisions and plans regarding Qsymia (phentermine and topiramate extended-release) capsules CIV. These plans include further investments in high-value, consumer-focused digital media projects in support of obesity education and Qsymia, and focusing the Qsymia field sales organization of approximately 100 territories on the most productive target areas. Management will continue discussions with US and EU regulatory authorities regarding Qsymia development and potential cost-saving measures related to the planned cardiovascular outcomes trial (CVOT), and will aim to further improve corporate efficiency and control costs while maintaining and extending the value of avanafil. The company plans to discuss with U.S. regulatory authorities and key consultants potential cost-saving alternatives with respect to the Qsymia CVOT, known as AQCLAIM. The company is also in the process of pursuing approval for Qsymia in the EU and other key countries, as well as new indications in other chronic diseases such as obstructive sleep apnea (OSA) and type 2 diabetes. VIVUS plans to optimize spending while pursuing these potential objectives.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.